NCT04843098View on ClinicalTrials.gov

Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

November 20, 2024

Study Completion Date

June 30, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

TL117

TL117 capsules orally once daily

DRUG

Paclitaxel

Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.

Trial Locations (1)

200120

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Junde Biotechnology Co., Ltd

INDUSTRY